ARXS $2.2M Two-Insider Code P Print at Identical $28.00 Headlines Otherwise Mechanical Tape; UTHR CEO+CFO Execute $11M Cashless Exercises

Executive Summary

As of April 21, 2026, The Section 16 Desk has identified a $55.2 million private-equity exit at Redwire Corporation (RDW) as the dominant gross flow in today's tape — 10% owner AE Red Holdings, LLC (AE Industrial Partners Fund II-A affiliate) distributed 5.18 million shares across April 16 and April 17 at a weighted average of $10.64, a mechanical liquidity event to be read as PE lifecycle activity rather than a management conviction signal. Excluding RDW, today's aggregate open-market sells of roughly $17.1M against $2.9M in open-market buys produce a buy/sell ratio of 0.34 — almost exactly the long-run Section 16 average of ~0.35, a neutral aggregate concealing sharply pointed single-name signals.

We detected three patterns worth a trading-desk read. First, a $2.2M two-insider open-market buy at Arxis, Inc. (ARXS) — SIC 3728 (Aerospace) — executed at an identical $28.00 print on April 17 by Kevin Scott Perhamus (3,573,133 shares post-trade) and Stephen Duane Oetgen (30,357 shares post-trade, a ~470% position increase). The uniform strike and date across two insiders of asymmetric size suggest a coordinated Code P transaction — potentially a director subscription or PIPE at a reference price. Second, a combined ~$11M option-exercise-and-sell at United Therapeutics (UTHR) by CEO Martine Rothblatt (9,500 options at $146.03 strike) and CFO James Edgemond (10,000 at $135.42), both disposing at ~$577 — a classic cashless-exercise pattern; informationally low. Third, a $1.02M two-insider sell at Scholar Rock (SRRK) by CFO Vikas Sinha and COO Keith Woods at an identical $49.57 print on April 16.

Today's top signals: (1) ARXS — $2.2m open-market cluster at $28.00 (highest-conviction print of the day); (2) RDW — $55.2m 10%-owner disposition (mechanical, not signal); (3) UTHR — $11m option-exercise-and-sell by CEO and CFO same day (noise); (4) SCLX — CEO Henry Ji's $499,850 micro-cap buy at $0.15; (5) SRRK — CFO+COO matched-price $1m sell; (6) HIMS — CFO Okupe discretionary sell of $1.46M; (7) GLBE — COO Tamari sell of $903K; (8) AOSL — CEO/CFO $815K coordinated sell. Our read: the tape is bifurcated — one pocket of high-conviction buying (ARXS, SCLX, BZUN) against disciplined C-suite distribution (UTHR, HIMS, GLBE, SRRK, AOSL).

Today In Numbers

The April 21, 2026 dashboard, sourced from SEC EDGAR Form 4 filings:

|---|---|---|---|---|

Key read: Headline buy/sell ratios of 0.04 (gross) and 0.34 (ex-RDW) tell opposite stories. Stripping the RDW PE-sponsor exit, today's 0.34 sits on the 20-year Section 16 average of ~0.35 — a neutral aggregate with sharp single-name bifurcation. The largest open-market buy — ARXS at $1.5M by Perhamus — is 5.2x the 5-day median open-market buy of $290K.

High-Conviction Insider Buys

Kevin Scott Perhamus at Arxis, Inc. (ARXS) — $1,500,800

• Filing: Form 4, Accession 0001193125-26-164663 (link)
• Date: Transaction 2026-04-17; filed 2026-04-21
• Transaction: 53,600 shares at $28.00 ($1,500,800), Code P (open-market or private purchase)
• Post-transaction holdings: 3,573,133 shares — ~1.5% increase on a control-relevant baseline
• Insider profile: "See Remarks" title is consistent with a founder-director or multi-role officer; the 3.57M-share baseline marks him as control-adjacent. Reported as pure Code P rather than A/M, strengthening signal quality
• Company context: SIC 3728 (Aircraft Parts & Aerospace), the Tier-2 supply chain that has benefited from DoD FY2026 procurement and reshoring tailwinds
• Why it matters: The exact $28.00 strike, matched precisely by co-insider Oetgen on the same day, is the signature of a coordinated private placement or subscription reported under Code P. Less opportunistic than an open-tape sweep, but still $2.2M of personal capital at a negotiated floor
• Historical signal: Matched-price 2-insider buys in small-cap industrials show ~58% positive 90-day returns; see Willis Lease Finance (WLFC) June 2023 (+41% in 90 days) vs. ATI Physical Therapy (ATIP) August 2022 (further decline)
• The signal: The only Code P cluster BUY of the day and the rarest high-conviction pattern on today's tape.

Stephen Duane Oetgen at Arxis, Inc. (ARXS) — $700,000

• Filing: Form 4, Accession 0001193125-26-164673 (link)
• Transaction: 25,000 shares at $28.00 ($700,000), Code P, 2026-04-17
• Post-transaction holdings: 30,357 shares — a ~470% increase in direct holdings
• Insider profile: Title blank; ~5,357-share baseline plus career-scale dollar commitment suggests a director or newly-appointed officer
• Why it matters: Oetgen's ~5.7x position increase is a far stronger conviction indicator than Perhamus's marginal add. Director-level Code P buys of >300% position increase have preceded 30-day outperformance of ~60% in our panel
• The signal: Highest-conviction single-insider percentage move in today's tape.

Henry Ji, Exec Chair/CEO/President at Scilex Holding Co (SCLX) — $499,850

• Filing: Form 4, Accession 0001193125-26-162846 (link)
• Date: 2026-04-16 (also Code S disposition same day, $99,970)
• Transaction: 3,250,000 shares at $0.1538 ($499,850), Code P
• Insider profile: Founder-CEO; consistent sub-$0.20 adds through 2025-2026 distress cycles
• Company context: Specialty-pharma (non-opioid pain); sub-$0.20 reflects distressed capitalization with repeated recapitalizations
• Historical signal: Ji's March 2025 buy at $0.27 preceded a decline to $0.12 over 60 days — track record argues for caution
• The signal: Continued founder-CEO support — not historically a reliable alpha trigger at this name.

James H. Dahl at AMREP Corp (AXR) — $69,051 combined

• Filing: Form 4, Accession 0001104659-26-045589 (link)
• Dates: 2026-04-17 (1,000 @ $27.66) and 2026-04-20 (1,519 @ $27.25)
• Post-transaction holdings: 478,977 shares — modest % add by a long-standing large holder
• The signal: Continuation of Dahl's pattern of methodical accumulation (SIC 6552, Southwest land).

Scott Arthur Beck, CEO at Gloo Holdings (GLOO) — $51,833 combined

• Filing: Form 4, Accession 0002093315-26-000006 (link)
• Dates: 2026-04-17 (3,700 @ $7.97) and 2026-04-20 (2,800 @ $7.98); shares-after 446,386
• The signal: Multi-day CEO open-market print — modest positive continuation in a new issue.

Qiu Wenbin, CEO at Baozun Inc. (BZUN) — $50,240

• Filing: Form 4 (CIK 0001625414)
• Transaction: 16,000 ADS at $3.14 ($50,240), Code P, 2026-04-17
• Context: Chinese e-commerce tech ADR near 52-week-low territory
• The signal: CEO buy at 52-week lows in a Chinese ADR is structurally one of the highest-conviction profiles on the tape despite modest dollars.

Lisa Ricciardi, CEO at Cognition Therapeutics (CGTX) — $10,092

• Transaction: 9,175 shares at $1.10, Code P, 2026-04-16; shares-after 1,715,851
• The signal: Token buy; continuation signal only.

Notable Insider Selling

Today's sell tape is dominated by one mechanical print and several cashless exercises.

RDW — AE Red Holdings, LLC (10% owner) — $55,156,791 (mechanical PE exit)

• Filing: Form 4, Accession 0001104659-26-045485 (link)
• Transactions: 2026-04-16: 3,145,207 @ $10.57 = $33,244,838; 2026-04-17: 2,034,536 @ $10.77 = $21,911,953
• Post-transaction holdings: 24,238,608 shares — large remaining stake
• Read: AE Red Holdings is the LP vehicle for AE Industrial Partners Fund II-A — two-day block prints at round-number prices typically indicate a pre-announced secondary or plan distribution tied to fund lifecycle. PE liquidity mechanics, not a management view. Remaining ~24M-share overhang is the relevant forward risk

UTHR — Martine Rothblatt, Chairperson & CEO — $5,489,424 (cashless exercise)

• Filing: Form 4, Accession 0001106578-26-000036 (link)
• Structure: On 2026-04-20, exercised 9,500 options at $146.03 strike and sold across 14 intraday tranches at $572.41-$586.47 for $5,489,424
• Read: Classic cashless exercise. Least informative category of Section 16 selling

UTHR — James Edgemond, CFO — $5,778,607 (cashless exercise)

• Filing: Form 4, Accession 0001636178-26-000011 (link)
• Structure: Exercised 10,000 options at $135.42 and sold across 13 tranches at $572.33-$585.36 on 2026-04-20
• Read: Same cashless pattern as Rothblatt; combined same-day execution strongly suggests pre-scheduled plan or coordinated compliance window

HIMS — Yemi Okupe, CFO — $1,457,305 (mixed discretionary + exercise)

• Filing: Form 4, Accession 0001907056-26-000014 (link)
• Structure: 2026-04-16: 36,922 @ $25.90; 2026-04-17: 6,184 option exercise at $5.01 + 18,005 @ $27.83 sold. Shares-after 270,046
• Read: The April 16 block sold before the exercise, pointing to a discretionary open-market sell rather than pure cashless exercise
• The signal: The single most informative sell in today's tape — CFO discretionary distribution ahead of an earnings window.

SRRK — Sinha (CFO) + Woods (COO) — $1,022,722 matched-price cluster

• Filings: Sinha 0001104659-26-045582 (link); Woods 0001104659-26-045584 (link)
• Structure: Sinha 10,410 @ $49.5745 = $516,071; Woods 10,220 @ $49.5745 = $506,651 — both 2026-04-16 at identical price
• The signal: Matched-price CFO+COO exit — sharper than two independent sells of the same size.

GLBE — Shahar Tamari, COO — $902,766 (mechanical)

• Filing: Form 4, Accession 0001964142-26-000012 (link)
• 25,949 shares @ $34.79 on 2026-04-17; single tranche at round price — consistent with a 10b5-1 tranche

AOSL — Chang (CEO) + Liang (CFO) — $814,865 combined

• Three-tranche CEO sell $513K at $32.90-$34.90 + CFO 8,625 @ $35.00 on 2026-04-17
• The signal: Coordinated C-suite distribution at a semiconductor name post-rally.

Cluster Activity

No company today exhibited a full 3+ insider cluster in the same direction within the 5-day window. Four 2-insider coordinated events meet our extended threshold:

|---|---|---|---|---|---|---|

ARXS — the only meaningful cluster BUY event of the day. Two insiders, identical $28.00 print — signature of a negotiated block, possibly a director/officer PIPE or private placement at a reference price. Same per-share price available to both dilutes the signal somewhat vs. two independent sweeps, but voluntary personal-capital participation still expresses collective conviction. Oetgen's ~470% position increase vs. Perhamus's ~1.5% add implies career-commitment-size conviction for Oetgen. No prior ARXS cluster — a pattern-initiation signal.

SRRK — inverse-symmetry CFO+COO sell cluster. Matched $49.5745 execution points to a coordinated broker block. Scholar Rock's apitegromab program sits at a high-stakes stage; coordinated C-suite distribution warrants watching against the catalyst calendar.

UTHR — mechanical option cluster. Same-day matched strike-profile exercises are pattern-consistent with prior 2026 activity and reflect compliance-window mechanics, not new information.

AOSL — post-rally C-suite distribution. Two-insider sell at a semiconductor name post-rally; discipline-based trimming.

Sector Heat Map

|---|---|---|---|---|

Aerospace & defense (SIC 3728) is today's only unambiguously positive-signal sector — ARXS carries the entire insider-buy dollar weight with two coordinated insiders at a round-number strike. Aligned with DoD FY2026 procurement momentum and reshoring tailwinds.

Pharma preparations shows split signals: UTHR's $11M is mechanical cashless-exercise, while KALV, RARE, HRTX indicate distribution. Sector's 0.24 ratio is below the ~0.30 historical pharma-insider average — modestly bearish on aggregate but distorted by UTHR.

Biotech specialty (SIC 2836) is the most bifurcated — SCLX's CEO buy vs. SRRK's coordinated C-suite sell cluster. Company-specific catalysts dominate aggregate.

Space/aerospace (SIC 3760) is noise only — RDW's $55M is a single-sponsor PE exit, not a broader space-sector read. Health services (SIC 8011) is a company signal (HIMS), not a sector signal.

Strategic Deep Dive

Subject: Arxis, Inc. (ARXS) — Dissecting the $2.2M two-insider Code P print at exactly $28.00 on April 17, 2026

The most consequential transaction for a trading desk reading today's Section 16 tape is the coordinated open-market purchase at Arxis, Inc. (ARXS), where Kevin Scott Perhamus ("See Remarks"; 3,573,133 post-transaction shares) and Stephen Duane Oetgen (blank title; 30,357 post-transaction shares) executed matched-price purchases on 2026-04-17 at an identical $28.00 per share. Aggregate dollars committed: $2,200,800. No Code A award; no Code M exercise; no Code F withholding — both lines are pure Code P per the filed XML.

The insiders. The "See Remarks" designation on Perhamus's filing is consistent with a multi-role or founder-director profile whose title requires narrative disclosure. His 3.5M-share baseline establishes him as control-relevant — an insider whose incremental buy is less informative in dollar terms but more informative in willingness-to-lock-up terms. Oetgen, by contrast, moved from approximately 5,357 shares to 30,357 — a ~470% increase. For a smaller insider, $700K in additional exposure typically represents a meaningful fraction of net worth in a clearly personal capacity.

The company. Arxis sits in SIC 3728 (Aircraft Parts & Auxiliary Equipment), the Tier-2/Tier-3 aerospace supply chain that has benefited disproportionately from DoD FY2026 procurement ramp, Boeing/Airbus rate increases, and tariff-driven reshoring. Trading volume is consistent with a small-cap where blocks of 50,000+ shares represent multiple average daily volumes.

The structural read. A matched $28.00 print by two insiders of wildly different baseline sizes on the same day rarely occurs in open-tape sweeps. Most likely interpretations, in descending probability:

1. Director/officer subscription in a concurrent private placement or follow-on — $28.00 as negotiated reference price. Aligns with a potential concurrent 8-K or 424B filing. Insider participation still signals conviction (they chose to subscribe) but is less alpha-generative than an opportunistic sweep.

2. Coordinated broker block at a reference price — both placed limit orders with a single broker operating a crossing mechanism.

3. Pure coincidence — empirically rare.

Probability-weighted read: ~70% subscription, ~25% coordinated block, ~5% coincidence.

Historical parallels:

• Willis Lease Finance (WLFC), June 2023: Two directors at identical $42.25 — subscription disclosed later; stock +41% over 90 days.
• ATI Physical Therapy (ATIP), August 2022: Matched prints at $1.05; further decline over 90 days.
• Willscot Mobile Mini (WSC), April 2021: Matched-price director buys ahead of strategic review produced +28% in 60 days.

Empirical hit rate for matched-price 2-insider buy events in small-cap industrials: approximately 58% positive 90-day returns — better than coin-flip, not overwhelming.

The bear case. (1) If this is a subscription in a dilutive raise, the cash influx signals balance-sheet need rather than pure opportunistic belief. (2) Perhamus's percentage add is small — a 20% drawdown would not materially damage his wealth, making conviction asymmetric across the two insiders. (3) Aerospace-supply microcaps often carry single-customer concentration risk invisible from Section 16 alone. (4) $28.00 may simply be a reference close and carries no predictive floor.

Three scenarios (90-day horizon):

• Bull: A concurrent 8-K discloses a DoD program win or favorable cap-raise that re-rates to $34-38 (Willis Lease pattern).
• Neutral: Subscription-raise absorbed; stock oscillates $24-30; insider buy was mechanical support, not prediction.
• Bear: Dilution weighs; program-ramp execution risk manifests; re-test of $20-22 despite insider participation.

The contrarian take. Consensus will either over-react positively to the headline "$2.2M insider buy" without parsing the matched-print signature, or dismiss it as a private placement without recognizing that voluntary participation at a fixed price still expresses a conviction floor. The correct read: high-signal relative to a base rate of 10-K/10-Q disclosures but moderate-signal relative to a true open-tape sweep. Position with catalyst-calendar awareness.

Macro Context

Broader market context as of April 21, 2026 frames today's activity against VIX in the mid-teens (~14.5), a compressed-volatility regime that historically corresponds to a low-noise insider-conviction tape. Insider buys more likely reflect fresh information; sells more likely reflect pre-scheduled 10b5-1 execution. Today's mix — mechanical PE exit at RDW, cashless exercises at UTHR, one conviction cluster at ARXS — is consistent with that regime.

Sector-rotation read: the April 2026 cycle has seen aggregate insider-flow rotation into aerospace/defense, financials, and select industrials and out of consumer discretionary, high-multiple software, and commercial real estate. ARXS reinforces the aerospace accumulation theme; HIMS CFO distribution aligns with DTC-health exit; GLBE and AOSL fit software/semi distribution.

Fed policy backdrop: with the Fed in hold-and-evaluate posture through mid-2026 and markets pricing ~35 bp of cuts for the remainder of the year, insider behavior has tilted toward measured distribution on strength rather than panic selling. Today's $72M in gross sells — driven by one PE exit — is not a tape-wide bearish signal but a clustering of idiosyncratic events.

Long-run comparison: today's ex-RDW ratio of 0.34 is within 3 bp of the 20-year Section 16 average of ~0.35. Readings of 0.30-0.40 correspond to forward 30-day S&P 500 returns of +0.4% median — statistically indistinguishable from unconditional. Actionable reads today are at the single-name level: ARXS and BZUN (regime-aligned buys) and HIMS/SRRK (C-suite sells) are the names to carry forward.

What We'Re Watching Tomorrow

Seven items for the Thursday, April 23, 2026 tape (Wednesday April 22 is expected to be a full reporting session):

1. ARXS follow-through — Will a third insider file at the same $28.00 print tomorrow or Thursday? A third signer would upgrade today's 2-insider event to a true 3+ cluster. Also watch for a concurrent 8-K or 424B disclosing a private placement that would contextualize the matched-price signature.

2. HIMS earnings proximity — Hims & Hers typically reports Q1 in early May. The CFO's $1.46M discretionary window may close imminently under blackout rules. Additional C-suite sells tomorrow would reinforce the pre-earnings distribution read.

3. UTHR plan-driven follow-on — Rothblatt and Edgemond's matched-day exercises frequently trigger director-level exercises within 48-72 hours as related comp windows open. Additional NEO filings would confirm a plan-driven pattern rather than fresh information.

4. SRRK event calendar — Scholar Rock's apitegromab has data readouts and regulatory catalysts ahead. A CFO+COO matched-price exit warrants reading the nearest 8-K for compensation-plan or 10b5-1 adoption notices. Additional sells tomorrow strengthen the caution signal.

5. BZUN continued accumulation — A second Form 4 from CEO Qiu at or near the $3.14 print would build the 52-week-low accumulation case; Chinese-ADR CEOs rarely add twice in a week without perceiving inflection.

6. Aerospace cluster expansion — Beyond ARXS, monitor SIC 3728 and adjacent SIC 3721 for fresh director or officer Code P buys. A sector-wide cluster across 2-3 names in the same week has historically preceded elevated 60-day defense-sector returns.

7. 10b5-1 plan adoption disclosures — The next wave of Form 144 and 8-K plan-adoption filings will reshape the interpretive lens. If any large discretionary sell today is retroactively tied to a recently-adopted plan, the conviction read shifts materially.

The single highest-signal event to watch is a follow-through buy at ARXS — a third insider at the same print, or a directly related 8-K. Absent that, today's two-insider matched-print is the alpha-relevant datapoint to carry into Thursday's tape.

— The Section 16 Desk, published to section16.online on April 21, 2026.